Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition
McKenzie Crist, Benyamin Yaniv, Sarah Palackdharry, Maria A Lehn, Mario Medvedovic, Timothy Stone, Shuchi Gulati, Vidhya Karivedu, Michael Borchers, Bethany Fuhrman, Audrey Crago, Joseph Curry, Ubaldo Martinez-Outschoorn, Vinita Takiar, Trisha M Wise-Draper, McKenzie Crist, Benyamin Yaniv, Sarah Palackdharry, Maria A Lehn, Mario Medvedovic, Timothy Stone, Shuchi Gulati, Vidhya Karivedu, Michael Borchers, Bethany Fuhrman, Audrey Crago, Joseph Curry, Ubaldo Martinez-Outschoorn, Vinita Takiar, Trisha M Wise-Draper
Abstract
Background: Metformin slows tumor growth and progression in vitro, and in combination with chemoradiotherapy, resulted in high overall survival in patients with head and neck cancer squamous cell carcinoma (HNSCC) in our phase 1 clinical trial (NCT02325401). Metformin is also postulated to activate an antitumor immune response. Here, we investigate immunologic effects of metformin on natural killer (NK) and natural killer T cells, including results from two phase I open-label studies in patients with HNSCC treated with metformin (NCT02325401, NCT02083692).
Methods: Peripheral blood was collected before and after metformin treatment or from newly diagnosed patients with HNSCC. Peripheral immune cell phenotypes were evaluated using flow cytometry, cytokine expression by ELISA and/or IsoLight, and NK cell-mediated cytotoxicity was determined with a flow-based NK cell cytotoxicity assay (NKCA). Patient tumor immune infiltration before and after metformin treatment was analyzed with immunofluorescence. NK cells were treated with either vehicle or metformin and analyzed by RNA sequencing (RNA-seq). NK cells were then treated with inhibitors of significant pathways determined by RNA-seq and analyzed by NKCA, ELISA, and western blot analyses.
Results: Increased peripheral NK cell activated populations were observed in patients treated with metformin. NK cell tumor infiltration was enhanced in patients with HNSCC treated with metformin preoperatively. Metformin increased antitumorigenic cytokines ex vivo, including significant increases in perforin. Metformin increased HNSCC NK cell cytotoxicity and inhibited the CXCL1 pathway while stimulating the STAT1 pathway within HNSCC NK cells. Exogenous CXCL1 prevented metformin-enhanced NK cell-mediated cytotoxicity. Metformin-mediated NK cell cytotoxicity was found to be AMP-activated protein kinase independent, but dependent on both mechanistic target of rapamycin and pSTAT1.
Conclusions: Our data identifies a new role for metformin-mediated immune antitumorigenic function through NK cell-mediated cytotoxicity and downregulation of CXCL1 in HNSCC. These findings will inform future immunomodulating therapies in HNSCC.
Keywords: cytotoxicity, immunologic; head and neck neoplasms; immunity, cellular; immunotherapy; killer cells, natural.
Conflict of interest statement
Competing interests: None declared.
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Figures
References
- Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc 2016;91:386–96. 10.1016/j.mayocp.2015.12.017
- Brana I, Siu LL. Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription. Ann Oncol 2012;23:x178–85. 10.1093/annonc/mds322
- Georges P, Rajagopalan K, Leon C, et al. . Chemotherapy advances in locally advanced head and neck cancer. World J Clin Oncol 2014;5:966. 10.5306/wjco.v5.i5.966
- Chaturvedi AK, Engels EA, Pfeiffer RM, et al. . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294–301. 10.1200/JCO.2011.36.4596
- Chae YK, Arya A, Malecek M-K, et al. . Repurposing metformin for cancer treatment: current clinical studies. Oncotarget 2016;7:40767–80. 10.18632/oncotarget.8194
- Gulati S, Desai J, Palackdharry SM, et al. . Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. Cancer 2020;126:354–62. 10.1002/cncr.32539
- Lonardo E, Cioffi M, Sancho P, et al. . Metformin targets the metabolic Achilles heel of human pancreatic cancer stem cells. PLoS One 2013;8:e76518. 10.1371/journal.pone.0076518
- Queiroz EAIF, Puukila S, Eichler R, et al. . Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One 2014;9:e98207. 10.1371/journal.pone.0098207
- Zhang T, Guo P, Zhang Y, et al. . The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int J Mol Sci 2013;14:24603–18. 10.3390/ijms141224603
- Zakikhani M, Dowling RJO, Sonenberg N, et al. . The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 2008;1:369–75. 10.1158/1940-6207.CAPR-08-0081
- Sahra IB, Regazzetti C, Robert G. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1 2011.
- Vitale-Cross L, Molinolo AA, Martin D, et al. . Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res 2012;5:562–73. 10.1158/1940-6207.CAPR-11-0502
- Eikawa S, Nishida M, Mizukami S, et al. . Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A 2015;112:1809–14. 10.1073/pnas.1417636112
- Volarevic V, Misirkic M, Vucicevic L, et al. . Metformin aggravates immune-mediated liver injury in mice. Arch Toxicol 2015;89:437–50. 10.1007/s00204-014-1263-1
- Scharping NE, Menk AV, Whetstone RD, et al. . Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res 2017;5:9–16. 10.1158/2326-6066.CIR-16-0103
- Amin D, Richa T, Mollaee M, et al. . Metformin effects on FOXP3+ and CD8+ T cell infiltrates of head and neck squamous cell carcinoma. Laryngoscope 2020;130:E490–8. 10.1002/lary.28336
- Dobin A, Davis CA, Schlesinger F, et al. . STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15–21. 10.1093/bioinformatics/bts635
- Harrow J, Denoeud F, Frankish A, et al. . GENCODE: producing a reference annotation for ENCODE. Genome Biol 2006;7:S4–9. 10.1186/gb-2006-7-s1-s4
- Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440–5. 10.1073/pnas.1530509100
- Anders S, McCarthy DJ, Chen Y, et al. . Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat Protoc 2013;8:1765–86. 10.1038/nprot.2013.099
- He L, Zhu H-Y, Qin S-C, et al. . Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma. Blood Cancer J 2016;6:e45. 10.1038/bcj.2016.67
- Pasero C, Gravis G, Granjeaud S, et al. . Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget 2015;6:14360–73. 10.18632/oncotarget.3965
- Accomando WP, Wiencke JK, Houseman EA, et al. . Decreased NK cells in patients with head and neck cancer determined in archival DNA. Clin Cancer Res 2012;18:6147–54. 10.1158/1078-0432.CCR-12-1008
- Wulff S, Pries R, Börngen K, et al. . Decreased levels of circulating regulatory NK cells in patients with head and neck cancer throughout all tumor stages. Anticancer Res 2009;29:3053–7.
- Pallmer K, Oxenius A. Recognition and regulation of T cells by NK cells. Front Immunol 2016;7:251. 10.3389/fimmu.2016.00251
- Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41–51. 10.1038/nri1995
- Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008;27:5944–58. 10.1038/onc.2008.272
- Curry J, Johnson J, Tassone P, et al. . Metformin effects on head and neck squamous carcinoma microenvironment: window of opportunity trial. Laryngoscope 2017;127:1808–15. 10.1002/lary.26489
- Cabrero-de Las Heras S, Martínez-Balibrea E. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol 2018;24:4738–49. 10.3748/wjg.v24.i42.4738
- Kristófi R, Eriksson JW. Metformin as an anti-inflammatory agent: a short review. J Endocrinol 2021;251:R11–22. 10.1530/JOE-21-0194
- Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med 2014;2:57. 10.3978/j.issn.2305-5839.2014.06.01
- Terrén I, Orrantia A, Vitallé J, et al. . NK cell metabolism and tumor microenvironment. Front Immunol 2019;10:2278. 10.3389/fimmu.2019.02278
- Deng X-S, Wang S, Deng A, et al. . Metformin targets STAT3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012;11:367–76. 10.4161/cc.11.2.18813
- Bose A, Chakraborty T, Chakraborty K, et al. . Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 2008;8:10.
- Moy JD, Moskovitz JM, Ferris RL. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer 2017;76:152–66. 10.1016/j.ejca.2016.12.035
- Klöß S, Chambron N, Gardlowski T, et al. . Increased sMICA and TGFβ 1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells. Oncoimmunology 2015;4:e1055993. 10.1080/2162402X.2015.1055993
- Jia L, Song Q, Zhou C, et al. . Dihydroartemisinin as a putative STAT3 inhibitor, suppresses the growth of head and neck squamous cell carcinoma by targeting JAK2/STAT3 signaling. PLoS One 2016;11:e0147157. 10.1371/journal.pone.0147157
- Bharadwaj U, Eckols TK, Xu X, et al. . Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget 2016;7:26307–30. 10.18632/oncotarget.8368
- Besson L, Mery B, Morelle M, et al. . Cutting edge: mTORC1 inhibition in metastatic breast cancer patients negatively affects peripheral NK cell maturation and number. J Immunol 2021;206:2265–70. 10.4049/jimmunol.2001215
- Seo H, Jeon I, Kim B-S, et al. . IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours. Nat Commun 2017;8:1–14. 10.1038/ncomms15776
- Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016;17:1025–36. 10.1038/ni.3518
- Amin S, Lux A, O’Callaghan F. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. Br J Clin Pharmacol 2019;85:37–46. 10.1111/bcp.13780
- Chen X, Yan B, Lou H, et al. . Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis. Mol Immunol 2018;96:28–36. 10.1016/j.molimm.2018.02.005
- Messaoudene M, Frazao A, Gavlovsky PJ, et al. . Patient’s natural killer cells in the era of targeted therapies: role for tumor killers. Front Immunol 2017;8:683. 10.3389/fimmu.2017.00683
- Tumeh PC, Harview CL, Yearley JH, et al. . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–71. 10.1038/nature13954
Source: PubMed